LAST WEEK TODAY!

A summary of what was published on ProstateWarriors.com during the past week

Here I am with the fifth newsletter from the site. I hope I will be like Santa Prostate and bring you some exciting discovery by Christmas!

We also have a podcast if you prefer to listen to the newsletter, you can find it HERE.​

Clinical Research

• A0-252 Targets Aggressive Cancers: A Phase 1 clinical trial is evaluating the TACC3 inhibitor A0-252 in patients with various solid cancers. Early findings show a strong safety and efficacy profile, suggesting its potential as a treatment for these challenging cancers.
  ​
• Boosting the Immune System with LNCB74: Another Phase 1 clinical trial is underway for LNCB74, an antibody-drug conjugate (ADC) that targets the B7-H4 protein found on cancer cells. By neutralizing the immune-suppressing effects of B7-H4, LNCB74 aims to empower the immune system to better detect and destroy cancer cells.
  ​
• CAN-2409 Shows Promise for Localized Prostate Cancer: A completed Phase 3 clinical trial has demonstrated significant improvement in disease-free survival for patients with intermediate-to-high-risk localized prostate cancer receiving CAN-2409, a novel viral immunotherapy, in combination with standard radiation therapy. CAN-2409 utilizes a unique mechanism to trigger a targeted immune response against cancer cells.
  ​
• Invikafusp Alfa Offers Hope for Advanced Tumors: Invikafusp alfa (STAR0602) has shown early promise in Phase 1 and 2 trials (STARt-001) involving patients with advanced solid tumors who did not respond to anti-PD-1 therapy. This innovative treatment selectively activates specific T-cells to attack cancer.
  ​
• OP-3136 Enters Clinical Trials: A Phase 1 clinical trial is set to begin for OP-3136, a small molecule inhibitor of KAT6. This promising drug candidate aims to disrupt the growth and spread of cancer cells, including metastatic castration-resistant prostate cancer (mCRPC).
  ​
• Optimizing Radiopharmaceutical Sequencing for mCRPC: The RaLu study has successfully demonstrated the safety of sequencing Radium-223 and Lutetium-177 PSMA therapy in mCRPC management. A new trial, AlphaBet, is currently investigating the effectiveness and feasibility of administering these therapies simultaneously.
  ​
• Dietary Intervention Shows Potential in Slowing Prostate Cancer Growth: A clinical trial focusing on men with early-stage prostate cancer has yielded positive results. Findings suggest that a diet high in omega-3 fatty acids and low in omega-6 fatty acids, along with fish oil supplements, can slow down the rate of cancer cell proliferation.
  ​

Preclinical Research

• Researchers at the University of Ottawa are pioneering a new approach that combines mRNA and RNAi therapies, delivered through nanoparticles, to manipulate gene expression for enhanced therapeutic outcomes in cancer and cardiovascular disease. Their work will continue with further investigation in animal models.
  ​
• Pre-clinical studies are underway to assess the effectiveness of A0-252, a TACC3 inhibitor, in treating prostate cancer.
  ​​
• Scientists at Weill Cornell Medicine have made a significant discovery by identifying a family of genes capable of effectively halting prostate cancer cell growth. This breakthrough was achieved through the creation of artificial proteins that mimic a specific section of the androgen receptor.
  ​
• The development of cell-penetrating antibodies represents a major advancement in cancer treatment. These antibodies can penetrate cells and target molecules inside, significantly expanding the potential of antibody therapies. Research published in Oncotarget highlights progress in this area, particularly with the 3E10 antibody, which targets the intracellular protein RAD51 involved in DNA repair.
  ​
• Bioresorbable acoustic microrobots (BAMs), tiny robots designed for targeted drug delivery, have shown remarkable success in preclinical trials using mice with bladder tumors. The BAMs deliver therapeutics with greater precision than traditional methods, leading to a significant reduction in tumor size.
  ​
• A groundbreaking study published in Nature details the creation of the largest and most comprehensive atlas of human gut cells to date. This atlas provides an in-depth look at the various types of cells within the gut, which is the “headquarter” of our immune system, their locations, and how they interact.

And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.

If you this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
​
​
Have a great weekend!

Max